Loading provider…
Loading provider…
Hematology & Oncology Physician in Washington, DC
NPI: 1356340517Primary Practice Location
MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL
3800 Reservoir Rd NW, Washington, DC
Primary Employer
Mgmc, LLC
mgmcltd.co.uk
HQ Phone
Get Craig's Phone Numberphone_androidMobile
Get Craig's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardDC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 124 | 200 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 28 | 28 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 25 | 25 |
| 4 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | 30 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 13 | 21 |
Authors: Ma, Alice D, Kessler, Craig M, Al-Mondhiry, Hamid A B, Gut, Robert Z, Cooper, David L
Journal: Blood Coagul Fibrinolysis
Managing chronic pain in adults with haemophilia: current status and call to action.
Authors: Humphries, T J, Kessler, C M
Journal: Haemophilia
Publication Date: 2014-10-02
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
Authors: Alex Spyropoulos
Publication Date: 2010-11-12
Lead Sponsor: John Mascarenhas
Collaborators: Roche Pharma AG, The Leukemia and Lymphoma Society
Intervention / Treatment: DRUG: Pegasys, DRUG: RG7388
Lead Sponsor: Incyte Corporation
Intervention / Treatment: DRUG: Ruxolitinib, DRUG: Itacitinib
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: National Cancer Institute (NCI), Myeloproliferative Disorders-Research Consortium